Aurigene Tech Team, Author at Aurigene

December 21, 2011

by Aurigene Tech Team

Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology pathway

Lausanne, Switzerland, and Bangalore, India, April 14, 2011 – Debiopharm Group™ (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies

December 20, 2011

by Aurigene Tech Team

51st ICAAC conference

Aurigene to participate in the 51st ICAAC conference, in Chicago, Illinois Conference link: https://www.icaac.org/

December 20, 2011

by Aurigene Tech Team

242nd Meeting of the American Chemical Society

Aurigene to participate in the 242nd meeting of the American Chemical Society in Denver, Colarado, US. Conference link: www.airapt.org/?q=node/124

December 20, 2011

by Aurigene Tech Team

Society of Toxicologic Pathology

Aurigene to participate in Society of Toxicologic Pathology in Denver, Colarado, US.

December 20, 2011

by Aurigene Tech Team

CHI’s Sixth Annual Drug Discovery Chemistry conference

Aurigene to participate in the 6th Annual Drug Discovery Chemistry conference in San Diego, California Conference link: https://www.drugdiscoverychemistry.com/

December 16, 2011

by Aurigene Tech Team

Our Science

With about 500 scientists, Aurigene has developed deep expertise in various target classes >>More

December 16, 2011

by Aurigene Tech Team

Trackrecord

Track-record of over 40 programs in collaboration with some of the leading global Pharma partners >>More

December 16, 2011

by Aurigene Tech Team

Our Focus

A specialized, discovery stage biotech, developing novel and best-in-class therapies to treat Oncology & Inflammation >>More